Emblem Corp EMMBF

RE:RE:Seeking Alpha Article

[jgreen09]

The author also failed to take a couple of critical elements of Emblem's future strategy into account. 

First, he talks about how the Canntab/extended release pills have no discernible impact at this point, which is fine -- they don't, at this point. But he essentially doesn't factor them into his analysis, which is completely missing the boat.

Second, he writes as though Emblem is going to forever limit its operations to the Canadian market. I highly doubt that will be the case either.

Slow and steady but unspectacular growth? If you look solely at Canadian patient counts and oil sales, then yeah. But if you consider what might well happen if/when the company develops an effective time-release capsule and gets an export license, then "slow and steady growth" seems like the understatement of the century.